Kitasato Daiichi Sankyo Vaccine Joint Venture Company to Begin Operations

March 31, 2011

Corporate

For Immediate Release

Daiichi Sankyo Co., Ltd.
The Kitasato Institute

Tokyo, March 31, 2011 - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the launch on April 1 of the joint venture company, Kitasato Daiichi Sankyo Vaccine Co., Ltd. Daiichi Sankyo (head office: Chuo-ku, Tokyo; President and Representative Director: Joji Nakayama) and The Kitasato Institute (head office: Minato-ku, Tokyo; Chairman of the Board of Trustees: Tadayoshi Shiba) entered into a basic agreement for the creation of a joint venture company on July 30, 2010, formalizing the deal on November 30, 2010. Details of the new company are as follows.

Name of the company: 　Kitasato Daiichi Sankyo Vaccine Co., Ltd.

Establishment date:　 April 1, 2011

Location of headquarters:　 Kitamoto, Saitama Prefecture

Management:

　President Masahiro Okabe

　Executive Vice President Setsuo Arai

　Member of Board Shigehisa Yamazaki

　Outside Director Akira Nagano

　Outside Director Takeo Ishidate

　Outside Director Yoshikazu Takano

　Outside Director Akio Goto

Principal businesses:

● Manufacturing and marketing of biological drug products for humans and animals.

● Research and development of new vaccines using cutting-edge technologies together with KitasatoUniversity, other domestic and overseas universities, and research institutes.

● Activities with the purpose of international cooperation, such as supplying vaccines and supporting technologies for the manufacture of biological drug products for humans and animals.

● Other necessary activities required to develop the joint venture company’s business.

Corporate philosophy

To make continuous efforts to develop high quality vaccines that meet the needs of patients, and contribute to improvements in world health and to building a better society for tomorrow.

Vision for 2015

● Create synergy between Kitasato-ism and the Daiichi Sankyo spirit in order to enthusiastically conduct R&D for the creation of innovative vaccines.

● Contribute to public health and protect against pandemics through the development and manufacture of vaccines.

● Establish Daiichi Sankyo as the leading vaccine manufacturer in Japan by providing drugs optimally suited to meet the medical needs of customers.

● Produce a stable supply of high quality, low-cost vaccines to realize the industry’s top level of operational efficiency.

● Earn public trust by being a company that respects the needs of customers, investors, employees and their families.

Main products

・Diphtheria and tetanus toxoids and pertussis vaccine (Kitasato Daiichi Sankyo)

・Diphtheria and tetanus toxoids and pertussis vaccine syringe (Kitasato Daiichi Sankyo)

・Tetanus & diphtheria toxoids (Kitasato Daiichi Sankyo)

・Adsorbed tetanus toxoid syringe (Kitasato Daiichi Sankyo)

・MMR vaccine (Kitasato Daiichi Sankyo)

・Rubella vaccine (Kitasato Daiichi Sankyo)

・Mumps vaccine (Kitasato Daiichi Sankyo)

・Influenza HA vaccine (Kitasato Daiichi Sankyo)

・Influenza HA vaccine syringe (Kitasato Daiichi Sankyo)

＜For further information＞

　　　　　　　　　　　　　　　　　　　　　　　　　　　Corporate Communications Department, Daiichi Sankyo Company Ltd.

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Tel: +81-3-6225-1126（Public Relations）

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　 +81-3-6225-1125（Investor Relations）

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　FAX：+81-3-6225-1132

　　　　　　　　　　　　　　　　　　　　　　　　　　　Public Relations Department, Kitasato Institute

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　TEL: +81-3-5791-6215・6425

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　FAX：+81-3-5420-0644

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　E-mail：kohoh@kitasato-u.ac.jp

Back to index